Learn more about MDS at http://www.YouAndMDS.com
Rafael Bejar, MD, PhD, Director of the MDS Center of Excellence at the Moores Cancer Center of the University of San Diego, explains how testing for genetic mutations and chromosomal abnormalities can help your doctor personalize your MDS therapy. For example, riskbased therapy based on a 5q deletion can lead to therapy with lenalidomide and mutations on the IDH genes can lead to treatment with specific chemotherapy drugs.